| Not Yet Recruiting | ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab NCT07504796 | NYU Langone Health | Phase 4 |
| Not Yet Recruiting | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tum NCT07405086 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | A Phase II Trial of LM103 in Advanced Melanoma NCT07310784 | Suzhou BlueHorse Therapeutics Co., Ltd. | Phase 2 |
| Recruiting | A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanom NCT07099430 | Nanjing Leads Biolabs Co.,Ltd | Phase 1 / Phase 2 |
| Not Yet Recruiting | Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showin NCT07040436 | Oncodesign Precision Medicine | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma NCT07107178 | Biotroy Therapeutics | Phase 1 |
| Recruiting | AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors NCT07027488 | Yale University | Phase 1 |
| Enrolling By Invitation | HS-IT101 Injection in the Treatment of Advanced Melanoma NCT06941818 | Qingdao Sino-Cell Biomedicine Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progressio NCT07004335 | Hebei Medical University Fourth Hospital | Phase 4 |
| Recruiting | Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patient NCT06697301 | Eikon Therapeutics | Phase 2 / Phase 3 |
| Recruiting | NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma NCT06889766 | Centre Hospitalier Universitaire Vaudois | Phase 1 |
| Completed | Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Databa NCT07079644 | Bristol-Myers Squibb | — |
| Recruiting | Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progre NCT05629546 | Washington University School of Medicine | Phase 1 |
| Recruiting | FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma NCT06472661 | University of Virginia | EARLY_Phase 1 |
| Recruiting | A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma NCT06594991 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo) NCT05663775 | AHS Cancer Control Alberta | Phase 2 |
| Recruiting | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [ NCT06264180 | Replimune, Inc. | Phase 3 |
| Recruiting | High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial NCT06298734 | Fred Hutchinson Cancer Center | N/A |
| Recruiting | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) NCT06112314 | Immunocore Ltd | Phase 3 |
| Recruiting | Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma NCT06295159 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Unknown | Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma NCT03989895 | PrimeVax Immuno-Oncology Inc. | Phase 1 |
| Unknown | Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma NCT03990493 | PrimeVax Immuno-Oncology Inc. | Phase 1 |
| Active Not Recruiting | Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Mela NCT06640530 | Biocad | Phase 3 |
| Unknown | Impact of Anti PD-1 Therapy in Children, Adolescents and Young Adults (CAYA) Melanoma Patients NCT06281912 | Azienda Ospedaliera di Perugia | — |
| Recruiting | A Clinical Study of T3011 in Subjects With Advanced Melanoma NCT06214156 | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | Naltrexone and Propranolol Combined With Immunotherapy NCT05968690 | Sarah Weiss | Phase 1 |
| Recruiting | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer NCT05969860 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | ACT-TIL and ANV419 for Advanced Melanoma. NCT05869539 | University Hospital, Basel, Switzerland | Phase 1 |
| Recruiting | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor C NCT05967533 | University of California, Davis | Phase 1 |
| Active Not Recruiting | A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Adv NCT06112808 | Biocad | Phase 1 |
| Completed | A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of NCT05383170 | Cytovation AS | Phase 1 / Phase 2 |
| Unknown | Safety and Efficacy of DCB-BO1301 in Advanced Melanoma NCT02994498 | Chung Mei Biopharma Co., Ltd | Phase 1 / Phase 2 |
| Terminated | XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Th NCT05695898 | University of California, San Francisco | Phase 1 |
| Unknown | PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma NCT05466474 | Henan Cancer Hospital | Phase 2 |
| Recruiting | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) NCT05549297 | Immunocore Ltd | Phase 3 |
| Active Not Recruiting | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma NCT05529316 | Agenus Inc. | Phase 2 |
| Unknown | A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression) NCT05135715 | RemeGen Co., Ltd. | Phase 2 |
| Unknown | A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation NCT05114603 | Shanghai Henlius Biotech | Phase 2 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma NCT04951583 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 |
| Completed | Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma NCT05105100 | University of California, San Francisco | — |
| Recruiting | A Study of GC101 TIL in Advanced Melanoma (10hospital) NCT05098184 | Shanghai Juncell Therapeutics | EARLY_Phase 1 |
| Recruiting | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | FLX475 in Combination With Ipilimumab in Advanced Melanoma NCT04894994 | RAPT Therapeutics, Inc. | Phase 2 |
| Completed | Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma NCT04796194 | Lytix Biopharma AS | Phase 2 |
| Terminated | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progress NCT04902040 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma NCT04698187 | Regeneron Pharmaceuticals | Phase 2 |
| Terminated | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma NCT04695977 | Regeneron Pharmaceuticals | Phase 2 / Phase 3 |
| Active Not Recruiting | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV NCT04462406 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Unknown | Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcino NCT04871334 | Shandong TheraWisdom Biopharma Co., Ltd. | Phase 1 |
| Unknown | Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut NCT05274438 | Peking University Cancer Hospital & Institute | Phase 2 |
| Completed | Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma NCT04493203 | Yana Najjar | Phase 2 |
| Unknown | Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical NCT05120024 | MelanomaPRO, Russia | — |
| Completed | Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma NCT04165967 | University Hospital, Basel, Switzerland | Phase 1 |
| Active Not Recruiting | A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Mela NCT04495257 | Yale University | Phase 1 |
| Completed | A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma NCT04640545 | Nanjing Leads Biolabs Co.,Ltd | Phase 1 |
| Completed | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study NCT03707574 | National Cancer Institute (NCI) | — |
| Unknown | Nab-PCE vs PC for MM After Failure of Anti-PD-1 NCT03917069 | Peking University Cancer Hospital & Institute | Phase 2 |
| Unknown | Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII NCT03818893 | Osaka University | Phase 2 |
| Completed | Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-P NCT03776136 | Merck Sharp & Dohme LLC | Phase 2 |
| Terminated | Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression NCT03724968 | Elizabeth Davis | Phase 2 |
| Completed | Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database NCT05426239 | Bristol-Myers Squibb | — |
| Completed | A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizuma NCT03815058 | Genentech, Inc. | Phase 2 |
| Terminated | Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) NCT03407170 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma NCT03501368 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcin NCT03502330 | Yale University | Phase 1 |
| Active Not Recruiting | Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma NCT02965716 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma NCT03311308 | Yana Najjar | Phase 1 |
| Unknown | A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma NCT03422445 | Peking University Cancer Hospital & Institute | Phase 2 |
| Completed | Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma NCT03200847 | University of Colorado, Denver | Phase 1 / Phase 2 |
| Active Not Recruiting | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY NCT02650986 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Unknown | Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer a NCT03086174 | Shanghai Junshi Bioscience Co., Ltd. | Phase 1 |
| Completed | Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer NCT02981303 | HiberCell, Inc. | Phase 2 |
| Unknown | Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Me NCT03013101 | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 |
| Completed | A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma NCT02738489 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Withdrawn | A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM) NCT02663258 | Royal Marsden NHS Foundation Trust | Phase 2 |
| Completed | Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepat NCT02402699 | Bristol-Myers Squibb | — |
| Completed | YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey NCT02224768 | Bristol-Myers Squibb | — |
| Completed | The Oncopanel Pilot (TOP) Study NCT02171286 | British Columbia Cancer Agency | — |
| Completed | A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or M NCT02177110 | Cancer Trials Ireland | — |
| Completed | PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Mela NCT01621490 | Bristol-Myers Squibb | Phase 1 |
| Unknown | Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma NCT01614301 | University of Regensburg | Phase 1 / Phase 2 |
| Completed | An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Ag NCT01618136 | Eisai Limited | Phase 1 / Phase 2 |
| Terminated | Phase II FANG™ in Advanced Melanoma NCT01453361 | Gradalis, Inc. | Phase 2 |
| Active Not Recruiting | Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot B NCT01134614 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma NCT01212276 | Morphotek | Phase 1 |
| Completed | Phase II Study of Tesetaxel in Metastatic Melanoma NCT01064713 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma NCT00920907 | Bristol-Myers Squibb | Phase 1 |
| Completed | Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine NCT00796991 | Bristol-Myers Squibb | Phase 1 |
| Unknown | Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma NCT00813449 | Simcere Pharmaceutical Co., Ltd | Phase 2 |
| Completed | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma. NCT00688090 | Mannkind Corporation | Phase 1 |
| Completed | A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine NCT00542893 | Genta Incorporated | Phase 1 |
| Completed | Dendritic Cell Based Therapy of Malignant Melanoma NCT00197912 | Herlev Hospital | Phase 1 / Phase 2 |
| Terminated | Study of Temzolomide and Gleevec in Advanced Melanoma NCT00667953 | Abramson Cancer Center at Penn Medicine | Phase 1 / Phase 2 |
| No Longer Available | An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma NCT06590480 | Replimune, Inc. | — |